Slate Medicines

Biotech & Life Sciences · Raleigh, United States · Founded 2026

Anti-PACAP monoclonal antibody for migraine prevention MoreLess

Slate Medicines is a biotechnology company developing next-generation therapeutics targeting PACAP for the prevention and treatment of migraines and related headache disorders. The company focuses on injectable therapies, including monoclonal antibodies, with potential at-home administration. Led by experienced biopharma executives, Slate aims to advance innovative migraine treatments where previous approaches have struggled, leveraging licensed assets and proprietary research to build a pipeline of headache disorder therapies.

Keywords: migraine, headache, therapeutics, PACAP, monoclonal antibody, injectable, at-home dosing, biotech, clinical development, health

Valuation $500M–1B

Headcount <100

Total funding $100–500M

Unlock exact values

Company overview

Slate Medicines company information

The essential company record, classifications and operating signals in one place.

Status: Operational
Founded: 2026
Headquarters: Raleigh, United States
Employees: 7
Open positions: None listed
Dealroom signal: 84.4

Website ↗LinkedIn ↗

client focusb2bsub industryBioTechnologybusiness modelManufacturingindustryHealthsectorBiotechnologysectorDrug DevelopmentsectorNeurologysectorAntibodiessectorChronic DiseasesectorClinical TrialssectorBiotech and PharmasectorDT and LSsectorscience-based

Valuation & funding

Slate Medicines funding history

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
SERIES AOther financing	Feb 2026	$130M	$520M	Forbion Capital Partners · Foresite Capital · RA Capital Management	↗

Showing 1 recorded eventsUnlock the complete deal history →

Growth signals

Slate Medicines website traffic

Latest recorded traffic for Slate Medicines is 2.7K monthly website visits.

Latest monthly visits2.7K

Monthly website visits2 observations · Jun 2026–Jul 2026

Hover or focus a point to see its exact monthly valueCompare with peers →

Comparisons

Slate Medicines compared with similar companies

Dealroom’s weighted taxonomy model identifies the closest operating peers. Company identity and context stay open; selected comparison metrics preview what is available in the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
PRProAbtechSite-specific bioconjugation for enhanced, long-acting biological drugs.	Gwangju, South Korea	Operational	—	$20M	$50M
NMnQ MedicalNeurotechnology company allowing data defined disease management via typing signatures	Cambridge, United States	Operational
SBSparian BiosciencesClinical-stage biopharmaceuticals targeting CNS disorders with novel compounds and strategic collaborations	New York City, United States	Operational
ETEikonizo TherapeuticsDeveloping therapies to improve the treatment of human disease, specifically neurodegenerative diseases	Cambridge, United States	Operational
BSBi/ond SolutionsEmpowers biological innovation by engineering hardware solutions for cell-based assays	Delft, Netherlands	Closed
RTR1 TherapeuticsPharmaceutical therapies targeting neurological, metabolic and infectious conditions	Temecula, United States	Operational
SBShizhiyuan BiotechnologyInnovative monoclonal antibody drug development and manufacturing	China	Operational
FTFidra TherapeuticsMultifunctional antibody drug platform for neurodegenerative disorders	Somerville, United States	Operational

Showing 8 of the closest matchesCompare every metric →

Talent graph

Slate Medicines's talent

Book a demo to see the people

Team profiled 2 named & role-tagged

Founders /100 quality score

Key operators 2 quality /100

Potential founders likely future founders

Startup mafia alumni-founded startups

Talent movements in · out past 12 months

Source: Dealroom Talent Intelligence.

Investors

3 investors on Slate Medicines's cap table

Sourced from Dealroom's funding and investor records. Investor profile links are shown where available.

Series A 3 investors entered at this stage

Forbion Capital Partners

Foresite Capital

RA Capital Management

Global footprint

Where Slate Medicines has talent and traffic

Workforce by country

2 countries with
team presence

🇺🇸 United States75%

🇩🇪 Germany25%

2 countries shown

In the news

Latest news about Slate Medicines

Recent press, funding announcements, and product moves mentioning Slate Medicines — open to read from the original sources.

See all news

Market sentiment

What the market is saying about Slate Medicines

An AI-synthesized read of the highest-engagement posts about Slate Medicines on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Slate Medicines’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Request a free trial

Takes under a minute. Already use Dealroom? Log in.